Imagine a world where prostate cancer could be detected and prevented before it even becomes a threat. Sounds like science fiction, right? But here's where it gets groundbreaking: MyOme, a pioneer in clinical whole-genome testing, has just launched the Prostate Cancer Integrated Polygenic Risk Score™ (iPRS) test, a revolutionary tool poised to transform how we approach men's health. This isn't just another screening test—it's a game-changer that uncovers hidden genetic risks beyond what traditional methods can detect, offering millions of men the chance for earlier, more precise care.
And this is the part most people miss: While we often associate prostate cancer risk with specific gene mutations like BRCA2 or HOXB13, the truth is that up to 95% of cases occur in men without these known variants. MyOme’s iPRS test steps in here, analyzing ~7 million genetic markers alongside clinical risk factors to provide a 10-year and lifetime risk assessment. This holistic approach delivers a clearer, more actionable understanding of an individual’s risk, filling a critical gap in current screening methods.
Here’s why this matters: Traditional prostate cancer screening, primarily reliant on PSA tests, is notoriously flawed. Up to 75% of elevated PSA results are false positives, leading to unnecessary procedures and anxiety. But here’s the controversial part: What if we could bypass these limitations entirely? Polygenic risk scores (PRS) like MyOme’s iPRS are proving to be a powerful alternative. In a landmark study, men in the top 10% of PRS were found to have a 3–4× higher risk of developing prostate cancer—and 72% of their cancers would have been missed by conventional screening. That’s not just a statistic; it’s a call to rethink how we detect and prevent this disease.
Dr. Akash Kumar, co-founder of MyOme, puts it succinctly: ‘By integrating genome sequencing with clinical risk factors, we can more precisely identify men at substantially increased risk and enable earlier screening and prevention strategies to ultimately improve outcomes.’ This isn’t just about catching cancer early—it’s about preventing it altogether through personalized care.
But here’s where it gets even more intriguing: MyOme’s iPRS test isn’t just for men with a family history of prostate cancer. In internal validation, 8.6% of men with no family history were identified as high-risk and had a threefold higher incidence of the disease. This raises a thought-provoking question: Should PRS testing become a standard part of men’s health screenings, regardless of family history? We’d love to hear your thoughts in the comments.
The Prostate Cancer iPRS test is now available for men aged 30–75 with no personal history of the disease or known pathogenic variants. Results are delivered via MyOme’s secure portal and should be interpreted by a clinician, with genetic counseling available as needed. This test joins MyOme’s growing suite of Proactive Health offerings, including tools for assessing risks of coronary artery disease, type 2 diabetes, breast cancer, and more. Together, these tests are shifting the paradigm from reactive medicine to precision prevention.
Here’s the bottom line: Prostate cancer doesn’t have to be a silent threat. With tools like MyOme’s iPRS test, we have the power to take control of our health like never before. But what do you think? Is this the future of men’s health, or are we moving too fast? Let us know in the comments—we’re eager to hear your perspective.
